Histological and serological tumor markers of gastric cancer

Histological and Serological Tumor Markers and Gene Expression and Their Clinical Usefulness in Cancers

Volumn , Issue , 2009, Pages 93-111

  Yasui, Wataru ^a   Sentani, Kazuhiro ^a   Sakamoto, Naoya ^a   Motoshita, Junichi ^a   Oue, Naohide ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

CA 72 4; CEA; Cell adhesion molecule; Cell cycle regulator; DNA methylation; Gastric cancer; Growth factor; Histological prognostic factor; Matrix metalloproteinase; Serial analysis of gene expression; Serological tumor marker

Indexed keywords

EID: 84973908713     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (92)

1. Pisani P, Bray F, Parkin DM. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int. J. Cancer. 2002, 97: 72-81.
2. Parkin DM. International variation. Oncogene. 2004, 23: 6329-6340.
3. Ossandon FJ, Villarroel C, Aguayo F, Santibanez E, Oue N, Yasui W, Corvalan AH. In silico analysis of gastric carcinoma serial analysis of gene expression libraries reveals different profiles associated with ethnicity. Mol. Cancer. 2008, 7: 22-30.
4. Ohgaki H, Matsukura N. Stomach cancer. In: World Cancer Report, Eds B.W. Stewart, P. Kleihues P. IARC Press, Lyon, 2003, pp 194-197.
5. Yasui W, Oue N, Ono S, Mitani Y, Ito R, Nakayama H. Histone acetylation and gastrointestinal carcinogenesis. Ann. N.Y. Acad. Sci. 2003, 983: 220-231.
6. Ushijima T, Sasako M. Focus on gastric cancer. Cancer Cell. 2004, 5: 121-125.
7. Yasui W, Oue N, Kitadai Y, Nakayama H. Recent advances in molecular pathobiology of gastric carcinoma. In: The diversity of gastric carcinoma. Eds M. Kaminishi, K. Takubo and K. Mafune. Springer-Verlag, Tokyo, 2005, pp 51-71.
8. Yasui W, Sentani K, Motoshita J, Nakayama H. Molecular pathobiology of gastric cancer (review). Scand. J. Surg. 2006, 95: 225-231.
9. Seregni E, Ferrari L, Martinetti A, Bombardieri E. Diagnostic and prognostic tumor markers in the gastrointestinal tract. Semin. Surg. Oncol. 2001, 20: 147-166.
10. Miki K, Urita Y. Using serum pepsinogens wisely in a clinical practice. J. Dig. Dis. 2007, 8: 8-14.
11. Miki K, Morita M, Sasajima M, Hoshina R, Kanda E, Urita Y. Usefulness of gastric cancer screening using the serum pepsinogen test method. Am. J. Gastroenterol. 2003, 98: 735-739.
12. Watanabe H, Mitsushima T, Yamaji Y, Okamoto M, Wada R, Kokubo T, Doi H, Yoshida H, Kawabe T, Omata M. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut. 2005, 54: 740-742.
13. Knekt P, Teppo L, Aromaa A, Rissanen H, Kosunen TU. Helicobacter pylori IgA and IgG antibodies, serum pepsinogen I and the risk of gastric cancer: changes in the risk with extended follow-up period. Int. J. Cancer. 2006, 119: 702-705.
14. Guadagni F, Roselli M, Amato T, Cosimelli M, Perri P, Casale V, Carlini M, Santoro E, Cavaliere R, Greiner JW, et al. CA 72-4 measurement of tumor-associated glycoprotein 72 (TAG-72) as a serum marker in the management of gastric carcinoma. Cancer Res. 1992, 52: 1222-1227.
15. Kodera Y, Yamamura Y, Torii A, Uesaka K, Hirai T, Yasui K, Morimoto T, Kato T, Kito T. The prognostic value of preoperative serum levels of CEA and CA19-9 in patients with gastric cancer. Am. J. Gastroenterol. 1996, 91: 49-53.
16. Kochi M, Fujii M, Kanamori N, Kaiga T, Kawakami T, Aizaki K, Kasahara M, Mochizuki F, Kasakura Y, Yamagata M. Evaluation of serum CEA and CA19-9 levels as prognostic factors in patients with gastric cancer. Gastric Cancer. 2000, 3: 177-186.
17. Takahashi Y, Takeuchi T, Sakamoto J, Touge T, Mai M, Ohkura H, Kodaira S, Okajima K, Nakazato H (Tumor Marker Committee). The usefulness of CEA and/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study. Gastric Cancer. 2003, 6: 142-145.
18. Colcher D, Horan Hand P, Nuti M, Schlom JA. A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc. Natl. Acad. Sci. U.S.A. 1981, 78: 3199-3203.
19. Wobbes T, Thomas CM, Segers MF, Nagengast FM. Evaluation of seven tumor markers (CA 50, CA 19-9, CA 19-9 TruQuant, CA 72-4, CA 195, carcinoembryonic antigen, and tissue polypeptide antigen) in the pretreatment sera of patients with gastric carcinoma. Cancer. 1992, 69: 2036-2041.
20. Safi F, Kuhns V, Beger HG. Comparison of CA 72-4, CA 19-9 and CEA in the diagnosis and monitoring of gastric cancer. Int. J. Biol. Makers. 1995, 10: 100-106.
21. Louhimo J, Kokkola A, Alfthan H, Stenman UH, Haglund C. Preoperative hCGbeta and CA 72-4 are prognostic factors in gastric cancer. Int. J. Cancer. 2004, 111: 929-933.
22. Yasui W, Oue N, Kuniyasu H, Ito R, Tahara E, Yokozaki H. Molecular diagnosis of gastric cancer: present and future. Gastric Cancer. 2001, 4: 113-121.
23. Kitadai Y, Haruma K, Sumii K, Yamamoto S, Ue T, Yokozaki H, Yasui W, Ohmoto Y, Kajiyama G, Fidler IJ, Tahara E. Expression of IL-8 correlates with vascularity in Human Gastric Carcinomas. Am. J. Pathol. 1998, 152: 93-100.
24. Kabir S, Daar GA. Serum levels of interleukin-1, interleukin-6 and tumor necrosis factor-alpha in patients with gastric carcinoma. Cancer Lett. 1995, 95: 207-212.
25. Macri A, Versaci A, Loddo S, Scuderi G, Travagliante M, Trimarchi G, Teti D, Famulari C. Serum levels of interleukin 1beta and interleukin 8 and tumor necrosis factor alpha as markers of gastric cancer. Biomarkers. 2006, 11: 184-193.
26. Konturek SJ, Starzynska T, Konturek PC, Karczewska E, Marlicz K, Lawniczak M, Jaroszewicz-Heigelman H, Biolanski W, Hartwich A, Ziemniak A, Hahn EG. Helicobacter pylori and CagA status, serum gastrin, interleukin-8 and gastric acid secretion in gastric cancer. Scand. J. Gastroenterol. 2002. 37: 891-898.
27. Murakami S, Satomi A, Ishida K, Murai H, Matsuki M, Hashimoto T. Serum-soluble interleukin-2 receptor concentrations in patients with gastric cancer. Cancer. 1994, 74: 2745-2748.
28. Murakami S, Okubo K, Tsuji Y, Sakata H, Hamada S, Hirayama R. Serum interleukin-12 levels in patients with gastric cancer. Surg. Today. 2004. 34: 1014-1019.
29. Kawabata T, Ichikura T, Majima T, Seki S, Chochi K, Takayama E, Hiraide H, Mochizuki H. Preoperative serum interleukin-18 level as a postoperative prognostic marker in patients with gastric carcinoma. Cancer. 2001, 92: 2050-2055.
30. Karayiannakis AJ, Syrigos KN, Polychronidis A, Zbar A, Kouraklis G, Simopoulos C, Karatzas G. Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery. Ann. Surg. 2002, 236: 37-42.
31. Wang TB, Deng MH, Qiu WS, Dong WG. Association of serum vascular endothelial growth factor-C and lymphatic vessel density with lymph node metastasis and prognosis of patients with gastric cancer. World J. Gastroenterol. 2007, 13: 1794-1797.
32. Lin Y, Kikuchi S, Obata Y, Yagyu K (Tokyo Research Group on Prevention of Gastric Cancer). Serum levels of transforming growth factor beta1 are significantly correlated with venous invasion in patients with gastric cancer. J. Gastroenterol. Hepatol. 2006, 21: 432-437.
33. Tanaka K, Miki C, Wakuda R, Kobayashi M, Tonouchi H, Kusunoki M. Circulating level of hepatocyte growth factor as a useful tumor marker in patients with early-stage gastric carcinoma. Scand. J. Gastroenterol. 2004, 39: 754-760.
34. Wu CY, Wu MS, Chiang EP, Chen YJ, Chen CJ, Chi NH, Shih YT, Chen GH, Lin JT. Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution. Clin. Cancer Res. 2007, 13: 2054-2060.
35. Yang YH, Deng H, Li WM, Zhang QY, Hu XT, Xiao B, Zhu HH, Geng PL, Lu YY. Identification of matrix metalloproteinase 11 as a predictive tumor marker in serum based on gene expression profiling. Clin. Cancer Res. 2008, 14: 74-81.
36. Aung PP, Oue N, Mitani Y, Nakayama H, Yoshida K, Noguchi T, Bosserhoff AK, Yasui W. Systematic search for gastric cancer-specific genes based on SAGE data: melanoma inhibitory activity and matrix metalloproteinase-10 are novel prognostic factors in patients with gastric cancer. Oncogene. 2006, 25: 2546-2557.
37. Wang CS, Wu TL, Tsao KC, Sun CF. Serum TIMP-1 in gastric cancer patients: a potential prognostic biomarker. Ann. Clin. Lab. Sci. 2006, 36: 23-30.
38. Chan AO, Lam SK, Chu KM, Lam CM, Kwok E, Leung SY, Yuen ST, Law SY, Hui WM, Lai KC, Wong CY, Hu HC, Lai CL, Wong J. Soluble E-cadherin is a valid prognostic marker in gastric carcinoma. Gut. 2001, 48: 808-811.
39. Chan AO, Chu KM, Lam SK, Cheung KL, Law S, Kwok KF, Wong WM, Yuen MF, Wong BC. Early prediction of tumor recurrence after curative resection of gastric carcinoma by measuring soluble E-cadherin. Cancer. 2005, 104: 740-746.
40. Benekli M, Gullu IH, Tekuzman G, Savas MC, Hayran M, Hascelik G, Firat D. Circulating intercellular adhesion molecule-1 and E-selectin levels in gastric cancer. Br. J. Cancer. 1998, 78: 267-271.
41. Tsigris C, Karayiannakis AJ, Syrigos KN, Zbar A, Diamantis T, Kalahanis N, Alexlou D. Clinical significance of soluble c-erbB2 levels in the serum and urine of patients with gastric cancer. Anticancer Res. 2002, 22: 3061-3065.
42. Attallah AM, Abdel-Aziz MM, El-Sayed AM, Tabll AA. Detection of serum p53 protein in patients with different gastrointestinal cancers. Cancer Detect. Prev. 2003, 27: 127-131.
43. Wurl P, Weigmann F, Meye A, Fittkau M, Rose U, Berger D, Rath FW, Dralle H, Taubert H. Detection of p53 autoantibodies in sera of gastric cancer patients and their prognostic relevance. Scand. J. Gastroenterol. 1997, 32: 1147-1151.
44. Oue N, Mitani Y, Motoshita J, Matsumura S, Yoshida K, Kuniyasu H, Nakayama H, Yasui W. Accumulation of DNA methylation is associated with tumor stage in gastric cancer. Cancer. 2006, 106: 1250-1259.
45. Lee TL, Leung WK, Chan MW, Ng EK, Tong JH, Lo KW, Chung SC, Sung JJ, To KF. Detection of gene promoter hypermethylation in the tumor and serum of patients with gastric carcinoma. Clin. Cancer Res. 2002, 8: 1761-1766.
46. Kanyama Y, Hibi Km Nakayama H, Kodera Y, Ito K, Akiyama S, Nakao A. Detection of p16 promoter hypermethylation in serum of gastric cancer patients.
47. Leung WK, To KF, Chu ES, Chan MW, Bai AH, Ng EK, Chan FK, Sung JJ. Potential diagnostic and prognostic values of detecting promoter hypermethylation in the serum of patients with gastric cancer. Br. J. Cancer. 2005, 92: 2190-2194.
48. Ikoma H, Ichikawa D, Daito I, Nobuyuki T, Koike H, Okamoto K, Ochiai T, Ueda Y, Yamagishi H, Otsuji E. Clinical application of methylation specific-polymerase chain reaction in serum of patients with gastric cancer. Hepatogastroenterology. 2007, 54: 946-950.
49. Yasui W, Oue N, Aung PP, Matsumura S, Shutoh M, Nakayama H. Molecularpathological prognostic factors of gastric cancer: a review. Gastric Cancer. 2005, 8: 86-94.
50. Yokozaki H, Yasui W, Tahara E. Genetic and epigenetic changes in stomach cancer. Int. Rev. Cytol. 2001, 204: 49-95.
51. Kim MA, Lee HS, Lee HE, Jeon YK, Yang HK, Kim WH. EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology. 2008, 52: 738-746.
52. Yonemura Y, Ninomiya I, Yamaguchi A, Fushida S, Kimura H, Ohoyama S, Niyazaki I, Endou Y, Tanaka M, Sasaki T. Evaluation of immunoreactivity for c-erbB2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res. 1991, 51: 1034-1038.
53. Takahashi Y, Cleary KR, Mai M, Kitadai Y, Bucana CD, Ellis LM. Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. Clin. Cancer Res. 1996, 2: 1679-1684.
54. Takahashi Y, Bucana CD, Akagi Y, Liu W, Cleary KR, Mai M, Ellis LM. Significance of platelet-derived endothelial cell growth factor in the angiogenesis of human gastric cancer. Clin. Cancer Res. 1998, 4: 429-434.
55. Kido S, Kitadai Y, Hattori N, Haruma K, Kido T, Ohta M, Tanaka S, Yoshihara M, Sumii K, Ohmoto Y, Chayama K. Interleukin 8 and vascular endothelial growth factor -prognostic factors in human gastric carcinoma? Eur. J. Cancer. 2001, 37: 1482-1487.
56. Lieto E, Ferraraccio F, Orditura M, Castellano P, Mura AL, Pinto M, Zamboli A, De Vita F, Galizia G. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann. Surg. Oncol. 2008, 15: 69-79.
57. Yasui W, Yokozaki H, Shimamoto F, Tahara H, Tahara E. Molecular-pathological diagnosis of gastrointestinal tissues and its contribution to cancer histopathology. Pathol. Int. 1999, 49: 763-774.
58. Kudo Y, Yasui W, Ue T, Yamamoto S, Yokozaki H, Nikai H, Tahara E. Overexpression of cyclin-dependent kinase-activating CDC25B phosphatase in human gastric carcinomas. Jpn. J. Cancer Res. 1997, 88: 947-952.
59. Yasui W, Kudo Y, Semba S, Yokozaki H, Tahara E. Reduced expression of cyclindependent kinase inhibitor p27Kip1 is associated with advanced stage and invasiveness of gastric carcinomas. Jpn. J. Cancer Res. 1997, 88: 625-629.
60. Xiangming C, Natsugoe S, Takao S, Hokita S, Tanabe G, Baba M, Kuroshima K, Aikou T. The cooperative role of p27 and cyclin E in the prognosis of advanced gastric carcinoma. Cancer. 2000, 89: 1214-1219.
61. Gamboa-Dominguez A, Seidl S, Reyes-Gutierrez E, Hermannstädter C, Quintanilla-Martinez L, Busch R, Höfler H, Fend F, Luber B. Prognostic significance of p21WAF1/CIP1, p27Kip1, p53 and E-cadherin expression in gastric cancer. J. Clin. Pathol. 2007, 60: 756-761.
62. Shimada Y, Yamasaki S, Hashimoto Y, Ito T, Kawamura J, Soma T, Ino Y, Nakanishi Y, Sakamoto M, Hirohashi S, Imamura M. Clinical significance of dysadherin expression in gastric cancer patients. Clin. Cancer Res. 2004, 10: 2818-2823.
63. Ito R, Oue N, Yoshida K, Kunimitsu K, Nakayama H, Nakachi K, Yasui W. Clinicopathological significant and prognostic influence of cadherin-17 expression in gastric cancer. Virchows Arch. 2005, 447: 717-722.
64. Yamauchi K, Uehara Y, Kitamura N, Nakane Y, Hioki K. Increased expression of CD44v6 mRNA significantly correlates with distant metastasis and prognosis in gastric cancer. Int. J. Cancer. 1998, 79: 256-262.
65. Mayer B, Jauch KW, Gunthert U, Figdor CG, Schildberg FW, Funke I, Johnson JP. Denovo expression of CD44 and survival in gastric cancer. Lancet 1993, 342: 1019-1022.
66. Yashiro M, Nishioka N, Hirakawa K. Decreased expression of the adhesion molecules desmoglein-2 is associated with diffuse-type gastric carcinoma. Eur. J. Cancer. 2006, 42: 2397-2403.
67. Sanada Y, Oue N, Mitani Y, Yoshida K, Nakayama H, Yasui W. Down-regulation of the claudin-18 gene, identified through serial analysis of gene expression data analysis, in gastric cancer with an intestinal phenotype. J. Pathol. 2006, 208: 633-642.
68. Yamashita K, Azumano I, Mai M, Okada Y. Expression and tissue localization of matrix metalloproteinase 7 (matrilysin) in human gastric carcinomas. Implications for vessel invasion and metastasis. Int. J. Cancer. 1998, 79: 187-194.
69. Liu XP, Kawauchi S, Oga A, Tsushimi K, Tsushimi M, Furuya T, Sasaki K. Prognostic significance of matrix metalloproteinase-7 (MMP-7) expression at the invasive front in gastric carcinoma. Jpn. J. Cancer Res. 2002, 93: 291-295.
70. Fujimoto D, Hirono Y, Goi T, Katayama K, Yamaguchi A. Prognostic value of protease-activated receptor-1 (PAR-1) and matrix metalloproteinase-1 (MMP-1) in gastric cancer. Anticancer Res. 2008, 28: 847-854.
71. Mrena J, Wiksten JP, Nordling S, Kokkola A, Ristimäki A, Haglund C. MMP-2 but not MMP-9 associated with COX-2 and survival in gastric cancer. J. Clin. Pathol. 2006, 59: 618-623.
72. Fondevila C, Metges JP, Fuster J, Grau JJ, Palacín A, Castells A, Volant A, Pera M. p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. Br. J. Cancer. 2004, 90: 206-215.
73. Pinto-de-Sousa J, Silva F, David L, Leitão D, Seixas M, Pimenta A, Cardoso-de-Oliveira M. Clinicopathological significance and survival influence of p53 protein expression in gastric carcinoma. Histopathology. 2004, 44: 323-331.
74. Sumiyoshi Y, Kakeji Y, Egashira A, Mizokami K, Orita H, Maehara Y. Overexpression of hypoxia-inducible factor 1alpha and p53 is a marker for an unfavorable prognosis in gastric cancer. Clin. Cancer Res. 2006, 12: 5112-5117.
75. Mrena J, Wiksten JP, Thiel A, Kokkola A, Pohjola L, Lundin J, Nordling S, Ristimäki A, Haglund C. Cyclooxygenase-2 is an independent prognostic factor in gastric cancer and its expression is regulated by the messenger RNA stability factor HuR. Clin. Cancer Res. 2005, 11: 7362-7368.
76. Seno H, Oshima M, Taniguchi MA, Usami K, Ishikawa TO, Chiba T, Taketo MM. CDX2 expression in the stomach with intestinal metaplasia and intestinal-type cancer: Prognostic implications. Int. J. Oncol. 2002, 21: 769-774.
77. Fan Z, Li J, Dong B, Huang X. Expression of Cdx2 and hepatocyte antigen in gastric carcinoma: correlation with histologic type and implications for prognosis. Clin. Cancer Res. 2005, 11: 6162-6170.
78. Velculescu VE, Zhang L, Vogelstein B, Kinzler KW. Serial analysis of gene expression. Science. 1995, 270: 484-487.
79. Yasui W, Oue N, Ito R, Kuraoka K, Nakayama H. Search for new biomarkers of gastric cancer through serial analysis of gene expression and its clinical implications. Cancer Sci. 2004, 95: 385-392.
80. Oue N, Hamai Y, Mitani Y, Matsumura S, Oshimo Y, Aung PP, Kuraoka K, Nakayama H, Yasui W. Gene expression profile of gastric carcinoma: identification of genes and tags potentially involved in invasion, metastasis, and carcinogenesis by serial analysis of gene expression. Cancer Res. 2004, 64: 2397-2405.
81. Hartupee JC, Zhang H, Bonaldo MF, Soares MB, Dieckgraefe BK. Isolation and characterization of a cDNA encoding a novel member of the human regenerating protein family: Reg IV. Biochim. Biophys. Acta. 2001, 1518: 287-293.
82. Oue N, Mitani Y, Aung PP, Sakakura C, Takeshima Y, Kaneko M, Noguchi T, Nakayama H, Yasui W. Expression and localization of Reg IV in human neoplastic and non-neoplastic tissues: Reg IV expression is associated with intestinal and neuroendocrine differentiation in gastric adenocarcinoma. J. Pathol. 2005, 207: 185-198.
83. Mitani Y, Oue N, Matsumura S, Yoshida K, Noguchi T, Ito M, Tanaka S, Kuniyasu H, Kamata N, Yasui W. Reg IV is a serum biomarker for gastric cancer patients and predicts response to 5-fluorouracil-based chemotherapy. Oncogene. 2007, 26: 4383-4389.
84. Kuniyasu H, Oue N, Sasahira T, Moriwaka Y, Shimomoto T, Fujii K, Ohmori H and Yasui W. Reg IV enhances peritoneal metastasis of gastric carcinomas. Cell Proliferat. 2008, (in press)
85. Zhang J, Liu WL, Tang DC, Chen L, Wang M, Pack SD, Zhuang Z, Rodgers GP. Identification and characterization of a novel member of olfactomedin-related protein family, hGC-1, expressed during myeloid lineage development. Gene. 2002, 283: 83-93.
86. Koshida S, Kobayashi D, Moriai R, Tsuji N, Watanabe N. Specific overexpression of OLFM4(GW112/HGC-1) mRNA in colon, breast and lung cancer tissues detected using quantitative analysis. Cancer Sci. 2007, 98: 315-320.
87. Oue N, Aung PP, Mitani Y, Kuniyasu H, Nakayama H, Yasui W. Genes involved in invasion and metastasis of gastric cancer identified by array-based hybridization and serial analysis of gene expression. Oncology. 2005, 69 Suppl 1: 17-22.
88. Zhang X, Huang Q, Yang Z, Li Y, Li CY. GW112, a novel antiapoptotic protein that promotes tumor growth. Cancer Res. 2004, 64: 2474-2481.
89. Liu W, Chen L, Zhu J, Rodgers GP. The glycoprotein hGC-1 binds to cadherin and lectins. Exp. Cell Res. 2006, 312: 1785-1797.
90. Blesch A, Bosserhoff AK, Apfel R, Behl C, Hessdoerfer B, Schmitt A, Jachimczak P, Lottspeich F, Buettner R, Bogdahn U. Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA. Cancer Res. 1994, 54: 5695-5701.
91. Sentani K, Oue N, Tashiro T, Sakamoto N, Nishisaka T, Fukuhara T, Taniyama K, Matsuura H, Arihiro K, Ochiai A, Yasui W. Immunohistochemical staining of Reg IV and claudin-18 is useful in the diagnosis of gastrointestinal signet ring cell carcinoma. Am. J. Surg. Pathol. 2008, (in press) Jun 18. [Epub ahead of print]
92. Sentani K, Oue N, Sakamoto N, Arihiro K, Aoyagi K, Sasaki H, Yasui W. Gene expression profiling with microarray and SAGE identifies PLUNC as a marker for hepatoid adenocarcinoma of the stomach. Mod. Pathol. 2008, 21: 464-475.